LivaNova
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell LivaNova and other ETFs, options, and stocks.About LIVN
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS).
LIVN Key Statistics
LIVN News
LivaNova PLC (NASDAQ:LIVN) Q1 2024 Earnings Call Transcript May 1, 2024 LivaNova PLC misses on earnings expectations. Reported EPS is $-0.77593 EPS, expectatio...
LivaNova ( ) First Quarter 2024 Results Key Financial Results Revenue: US$294.9m (up 12% from 1Q 2023). Net loss: US$41.9m (down from US$7.37m profit in 1Q 2...
On Thursday, LivaNova (LIVN) got an upgrade for its IBD SmartSelect Composite Rating from 90 to 96. X The new rating shows the stock is outpacing 96% of all st...
Analyst ratings
60%
of 10 ratingsMore LIVN News
Jefferies raised the firm’s price target on LivaNova to $90 from $82 and keeps a Buy rating on the shares following quarterly results. The firm remains encourag...
Revenue: Reported $294.9 million, a 12.0% increase year-over-year, exceeding estimates of $278.66 million. Adjusted Earnings Per Share (EPS): Achieved $0.73, s...
LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43...
Full-Year 2024 Guidance: LivaNova now expects revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis vs. estimated growth of 4...
Reports Q1 revenue $294.9M, consensus $278.66M. “In Q1, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuro...
LONDON, May 01, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended Ma...
LivaNova PLC ( NASDAQ: LIVN The consensus EPS Estimate is $0.49 (+14.0% Y/Y) and the consensus Revenue Estimate is $278.19M (+5.6% Y/Y).Over the last 2 years,...